Mar­ket­ingRx roundup: Phar­mas lay off Twit­ter ads for an­oth­er week; WPP un­cov­ers LGBTQ+ mar­ket­ing find­ings

When Twit­ter’s new own­er Elon Musk tweet­ed this week­end, “Just a note to thank ad­ver­tis­ers for re­turn­ing to Twit­ter,” he like­ly wasn’t talk­ing about big phar­ma com­pa­nies. The vast ma­jor­i­ty of the top spend­ing phar­ma ad­ver­tis­ers had not re­turned last week, ac­cord­ing to up­dat­ed track­ing da­ta Path­mat­ic for End­points News.

On­ly three phar­ma ad­ver­tis­ers spent any mon­ey at all, which is about the same as the past sev­er­al weeks. As­traZeneca re­joined the ac­tive ad­ver­tis­er list, al­though at $700 spent hard­ly worth a per­son­al Musk ex­pres­sion of grat­i­tude. GSK re­mained ac­tive with $3,500 spent ad much low­er than its pre­vi­ous spend­ing, ac­cord­ing to the Path­mat­ics da­ta. On­ly Bay­er spent any sig­nif­i­cant amount in ad­ver­tis­ing, with $244,000 spent last week, but that’s a con­sid­er­able drop from al­most $500,000 spent on OTC, pre­scrip­tion and cor­po­rate Twit­ter ads in each of the pre­vi­ous two weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER